“…Future application of STRO-1+cK-it+CD34+ DPSCs is based on their ability to form 3D sphere system, capacity to preserve immunological expression of STRO-1+cKit+CD34+ and expression of late neuronal differentiation markers, but also on maintaining capacity for osteogenic differentiation [47]. Specifically, STRO-1+cKit+FLK-1+CD34+ cells were reported to have the highest growth potential and neurogenic commitment, while STRO-1+cK-it+CD34+ alone express significantly more low affin- [11] general: STRO-1, CD29, CD44, CD73, CD90, CD105, CD146, CD166, CD271 hematopoietic: CD34 and CD117 stemness: OCT-3/4 and NANOG [25] CD13, CD29, CD105, CD146, CD166 [1] CD90, CD73, CD34 [49] STRO-1, c-Kit, CD29, CD34, CD44, CD73, CD105, CD146 [47] STRO-1, c-Kit, CD34 [15] CD90, CD73, CD34 ity nerve growth factor receptor (LNGFR) [47,48]. Therefore, mainly STRO-1+ DPSCs show generally firmer tendency for neurogenic commitment rather than other pulp cells expressing common mesenchymal markers [49,50].…”